Apollo aborts mission, investment fund licensed, biotechs move into Phase II trials and NuSep sorts its sperm.

LCT is set to start a pig islet transplantation trial for type 1 diabetes that may have a profound effect on the debate over Australia's xenotransplantation moratorium in 2009.

Melbourne gene-test company Genetic Technologies (ASX: GTG; NASDAQ: GENE) US rival Applera Technologies have sought additional time from the US District Court of Northern California to resolve the long-running licensing dispute between the companies.

The Australian Stock Exchange has created a market that attracts not only local biotechnology companies, but also gives opportunities to foreign companies that would be unable to attract capital in their own markets. Helen Schuller reports.

The incoming chief of Mayne Pharma, the global injectable drugs business soon to emerge from the break-up of Mayne Group (ASX:MAY), said growth would have to come from acquisitions and expansion into new areas.

Shares in AtCor Medical (ASX:ACG), the developer and marketer of a device to measure cardiovascular function, began trading on the Australian Stock Exchange today at $0.65, 7.5 per cent above its issue price of $0.50.

South Australia's LabTech Systems (NSX:LTS) has lodged a prospectus for an IPO to raise up to AUD$5.5 million to progress the development of its MicroStreak technology and assist in moving the company's shares and options from the Newcastle Stock Exchange to the Australian Stock Exchange.

Ruth Beran talks with Iatia boss Charles Laycock about the importance of being smart and flexible in designing a good biotech business model.

It's hardly surprising that one of the Australian biotechnology industry's biggest bugbears is a communication gap between companies and their investors.

Sydney-based gastrointestinal drug development company Giaconda (ASX:GIA) has listed today on the Australian Stock Exchange at AUD$0.585, eight cents above its issue price of $0.50.

Melbourne's Amrad Corporation (ASX:AML) has proposed that its name be changed to Zenyth Therapeutics.